

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>	<i>Complete if Known</i>	
	<b>Application Number</b>	10/723,365
	<b>Filing Date</b>	November 26, 2003
	<b>First Named Inventor</b>	Van den Boom
	<b>Group Art Unit</b>	1637
	<b>Examiner Name</b>	WOOLWINE, SAMUEL C
Sheet 1 of 3		Attorney Docket No: SEQ-2073-UT

US PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	11/997,402	1/30/2008	van den Boom	
	A2.	5,830,712	Nov-98	Rampersad et al.	
	A3.	5,948,902	Dec-04	Schembri et al.	
	A4.	6,090,549	Sep-99	Honkanen et al.	
	A5.	6,884,586	4/26/2005	Van Ness	
	A6.	2004/0014101	Jan-04	Liu et al.	
	A7.	2004/0253141	Dec-04	Schembri et al.	
	A8.	2005/0009059	1/13/2005	Shapero	
	A9.	2005/0019762	1/27/2005	Olek	
	A10.	2005/0064406	3/24/2005	Zabarovsky	
	A11.	2005/0064428	3/24/2005	Berlin	
	A12.	2005/0069879	3/31/2005	Berlin	
	A13.	2005/0153316	7/14/2005	Jeddeloh	
	A14.	2005/0153347	7/14/2005	Shapero	
	A15.	2005/0164246	Jul-05	Fan et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	A16.	WO 03/057909	7/17/2003	Berlin, Kurt		
	A17.	WO 02/086163	10/31/2002	Zabarovsky		
	A18.	WO 03/080863	10/1/1003	Berlin, Kurt		
	A19.	WO 04/013284	2/12/2004	Friso		

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)  
\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant to indicate citation designation number for internal use. Applicant to place a check mark next to English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>	<i>Complete if Known</i>	
	<b>Application Number</b>	10/723,365
	<b>Filing Date</b>	November 26, 2003
	<b>First Named Inventor</b>	Van den Boom
	<b>Group Art Unit</b>	1637
	<b>Examiner Name</b>	WOOLWINE, SAMUEL C
Sheet 2 of 3		Attorney Docket No: SEQ-2073-UT

	<b>A20.</b>	WO 05/040399	5/6/2005	Jeddeloh		
--	-------------	--------------	----------	----------	--	--

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	<b>A21.</b>	Aoki E. et al., "Methylation status of the p151NK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes", Leukemia 14(4):586-593 (2000)	
	<b>A22.</b>	Asimakopoulou FA et al., "ABL 1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia" Blood 94(7):2452-2460 (1999)	
	<b>A23.</b>	Bair and Tibshirani, PloS Biol 2:E108 (2004)	
	<b>A24.</b>	Bullinger L. et al. N Engl J Med 350:1605-16 (2004)	
	<b>A25.</b>	Chan et al., Oncogene 22:924-934 (2003)	
	<b>A26.</b>	Chen et al., Analytical Biochemistry, 1996, vol. 239, p. 61-69	
	<b>A27.</b>	Colella et al. Biotechniques. 2003 Jul;35(1):146-50	
	<b>A28.</b>	Costello et al., Nature Gent, 24:132-138 (2000)	
	<b>A29.</b>	Dohner et al. J Clin Oncol 20:3254-61 (2002)	
	<b>A30.</b>	Dupont JM, Tost J, Jammes H, and Gut IG. Anal Biochem, Oct 2004; 333(1): 119-27	
	<b>A31.</b>	Fajkusova L. et al., "Detailed Mapping of Methylcytosine Positions at the CpG Island Surrounding the Pa Promoter at the bcr-abl Locus in CML Patients and in Two Cell Lines, K562 and BV173" Blood Cells Mol. Dis. 26(3):193-204 (2000)	
	<b>A32.</b>	Feinberg, AP Nat Genet 27:9-10 (2001)	
	<b>A33.</b>	Frigola et al. Nat Genet. 2006 May;38(5):540-9	
	<b>A34.</b>	Frohling et al. Blood 100:4372-80 (2002)	
	<b>A35.</b>	Gebhard et al. Cancer Res. 2006 Jun 15;66(12):6118-28	
	<b>A36.</b>	Genebank Accession number NM_153620	
	<b>A37.</b>	Genebank Accession number AB025106	
	<b>A38.</b>	Genebank Accession number AB040880	
	<b>A39.</b>	Genebank Accession number BC013998	
	<b>A40.</b>	Genebank Accession number NM_001031680	
	<b>A41.</b>	Genebank Accession number NM_001394	
	<b>A42.</b>	Genebank Accession number NM_001614	
	<b>A43.</b>	Genebank Accession number NM_003998	
	<b>A44.</b>	Genebank Accession number NM_004350	
	<b>A45.</b>	Genebank Accession number NM_004360	
	<b>A46.</b>	Genebank Accession number NM_005522	
	<b>A47.</b>	Genebank Accession number NM_005766	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)  
 \* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant to indicate citation designation number (optional). Applicant to place a check mark next to English language translation if attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/723,365
<b>Filing Date</b>	November 26, 2003
<b>First Named Inventor</b>	Van den Boom
<b>Group Art Unit</b>	1637
<b>Examiner Name</b>	WOOLWINE, SAMUEL C

Sheet 3 of 3

Attorney Docket No: SEQ-2073-UT

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	<b>A48.</b>	Genebank Accession number NM_033317	
	<b>A49.</b>	Issa JP, Nat Rev Cancer 4:988-93 (2004)	
	<b>A50.</b>	Kaneko et al., Gut 52:641-646 (2003)	
	<b>A51.</b>	Laird, P.W. Nature Reviews Cancer 3, 253-266 (2003)	
	<b>A52.</b>	Litz C. E. et al., "Methylation status of the major breakpoint cluster region in Philadelphia chromosome negative leukemias" Leukemia 6(1):35-41 (1992)	
	<b>A53.</b>	Nosaka, K. et al., "Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia", Cancer Res. 60(4):1043-1048 (2000)	
	<b>A54.</b>	Puskas et al. Genome Research, 1995, vol. 5, p. 309-311	
	<b>A55.</b>	Schuetz et al. Journal of Pharmaceutical and Biomedical Analysis, 1995, vol. 13, p. 1195-1203	
	<b>A56.</b>	Strathdee, et al., Am. J. Pathol. 158:1121-1127 (2001)	
	<b>A57.</b>	Tooke N and Pettersson M. IVDT. Nov 2004; 41	
	<b>A58.</b>	Toyota, M. et al., Blood 97:2823-9 (2001)	
	<b>A59.</b>	Uhlmann, K. et al. Electrophoresis 23:4072-4079 (2002)	
	<b>A60.</b>	Valk PJ et al. N Engl J Med 350:1617-28 (2004)	

**EXAMINER**

/Samuel Woolwine/

**DATE CONSIDERED**

12/04/2008

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant to indicate citation designation number for formal Applicant to place a check mark next to English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./**